Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precancerous Conditions 3Lung Neoplasms 3Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Peripheral Blood Stem Cell Transplantation 25Whole-Body Irradiation 18Etoposide 18Doxorubicin 17Vincristine 16Mycophenolic Acid 16Cyclosporine 16Prednisone 15Tacrolimus 12Busulfan 12Bortezomib 12Methotrexate 11Antilymphocyte Serum 11Rituximab 10Melphalan 10Gemcitabine 9Carboplatin 9Lenalidomide 8Filgrastim 8Vorinostat 7Radiotherapy 7Everolimus 7Therapeutics 6Flow Cytometry 6Alemtuzumab 6romidepsin 5Methylprednisolone 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × Comparative Genomic Hybridization × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡